FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2507795054> ?p ?o ?g. }

• W2507795054 endingPage "1828" @default.
• W2507795054 startingPage "1828" @default.
• W2507795054 abstract "Abstract Pharmacological inhibition of the proteasome with bortezomib (BTZ) has translated into an improved clinical outcome in patients with multiple myeloma and mantle cell lymphoma. Despite the observed clinical activity, BTZ anti-tumor activity in B-cell lymphoma has been partially hindered by treatment-related toxicities (peripheral neuropathy) preventing further dose escalation and emergence of acquired resistance. To further develop therapeutic strategies targeting the proteasome system, we studied the anti-tumor activity and mechanisms-of-action of ixazomib (MLN2238), a reversible proteasome inhibitor, in pre-clinical lymphoma models. Previously we demonstrated that ixazomib is active in various lymphoma pre-clinical in vitro models and that is capable of inducing cancer cell death in a caspase-independent manner. To further explore the effects of ixazomib, we investigated its anti-tumor activity in murine lymphoma models and investigated the mechanisms responsible for cell death observed in our pre-clinical models. For in vivo studies, 6-8 week old severe combined immunodeficiency (SCID) mice were inoculated via tail vein injection (iv) with mantle cell lymphoma Granta cells (day 0) and assigned to observation, ixazomib (iv) (at 6mg/kg/dose on days +1, 4, 8, 11, 15 and 18) or BTZ (ip) (at 0.8mg/kg/dose on days +1, 4, 8, 11, 15, and 18). Differences in survival (measured as the time to limb paralysis development) were evaluated by log-rank test across treatment arms. In addition, we studied the role of p21 in the anti-tumor activity of ixazomib. A panel of rituximab-sensitive (RSCL) and -resistant cell lines (RRCL) was exposed to ixazomib. Changes in cell cycle distribution and expression levels of key cell cycle regulatory proteins were evaluated by Western blotting and flow cytometry respectively. To further define the role of p21 in ixazomib activity, transient p21 knock down was achieved using electroporation with a pooled p21 siRNA. Down regulation of p21 was confirmed by Western blotting. Following transient p21 knock down, RSCL or RRCL were exposed to ixazomib and changes in cell viability were determined using the cell titer glo assay. Finally, RSCL and RRCL were exposed to ixazomib (10nM) +/- the cell cycle inhibitor roscovitine (10nM) and viability was determined by measuring changes in ATP content. As single agent, ixazomib prolonged the survival of Granta-bearing SCID mice when compared to control or BTZ (median=24 vs. 27 vs. 35 days; P = 0.012). In addition, in vitro exposure of lymphoma cell lines to ixazomib resulted in p21 and cell cycle arrest in G1 (RSCL) or G2/M (RRCL). Transient knock down of p21 rescued both Raji RSCL and RRCL from the cytotoxic effects of ixazomib when compared to controls. Moreover, in vitro exposure of RSCL to ixazomib in the presence to roscovitine resulted in synergistic effects on cell viability. Together our data suggests that ixazomib is more effective than BTZ in controlling mantle cell lymphoma growth in vivo. In addition, MLN2238 anti-tumor activity appears to be mediated partially by the stabilization of p21. (Ixazomib was obtained from Millennium Pharmaceuticals, Inc. Research, in part, supported by a NIH grant R01 CA136907-01A1 awarded to Roswell Park Cancer Institute and The Eugene and Connie Corasanti Lymphoma Research Fund.) Disclosures: Czuczman: Genetech, Onyx, Celgene, Astellas, Millennium, Mundipharma: Advisory Committees Other." @default.
• W2507795054 created "2016-09-16" @default.
• W2507795054 creator A5025865972 @default.
• W2507795054 creator A5029079928 @default.
• W2507795054 creator A5042570714 @default.
• W2507795054 creator A5082370897 @default.
• W2507795054 date "2013-11-15" @default.
• W2507795054 modified "2023-09-28" @default.
• W2507795054 title "Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models" @default.
• W2507795054 doi "https://doi.org/10.1182/blood.v122.21.1828.1828" @default.
• W2507795054 hasPublicationYear "2013" @default.
• W2507795054 type Work @default.
• W2507795054 sameAs 2507795054 @default.
• W2507795054 citedByCount "1" @default.
• W2507795054 countsByYear W25077950542019 @default.
• W2507795054 crossrefType "journal-article" @default.
• W2507795054 hasAuthorship W2507795054A5025865972 @default.
• W2507795054 hasAuthorship W2507795054A5029079928 @default.
• W2507795054 hasAuthorship W2507795054A5042570714 @default.
• W2507795054 hasAuthorship W2507795054A5082370897 @default.
• W2507795054 hasConcept C126322002 @default.
• W2507795054 hasConcept C2776364478 @default.
• W2507795054 hasConcept C2777478702 @default.
• W2507795054 hasConcept C2777525834 @default.
• W2507795054 hasConcept C2778367456 @default.
• W2507795054 hasConcept C2779338263 @default.
• W2507795054 hasConcept C2780108899 @default.
• W2507795054 hasConcept C2781098529 @default.
• W2507795054 hasConcept C502942594 @default.
• W2507795054 hasConcept C71924100 @default.
• W2507795054 hasConcept C98274493 @default.
• W2507795054 hasConceptScore W2507795054C126322002 @default.
• W2507795054 hasConceptScore W2507795054C2776364478 @default.
• W2507795054 hasConceptScore W2507795054C2777478702 @default.
• W2507795054 hasConceptScore W2507795054C2777525834 @default.
• W2507795054 hasConceptScore W2507795054C2778367456 @default.
• W2507795054 hasConceptScore W2507795054C2779338263 @default.
• W2507795054 hasConceptScore W2507795054C2780108899 @default.
• W2507795054 hasConceptScore W2507795054C2781098529 @default.
• W2507795054 hasConceptScore W2507795054C502942594 @default.
• W2507795054 hasConceptScore W2507795054C71924100 @default.
• W2507795054 hasConceptScore W2507795054C98274493 @default.
• W2507795054 hasIssue "21" @default.
• W2507795054 hasLocation W25077950541 @default.
• W2507795054 hasOpenAccess W2507795054 @default.
• W2507795054 hasPrimaryLocation W25077950541 @default.
• W2507795054 hasRelatedWork W2058275417 @default.
• W2507795054 hasRelatedWork W2269989009 @default.
• W2507795054 hasRelatedWork W2564340835 @default.
• W2507795054 hasRelatedWork W2731570198 @default.
• W2507795054 hasRelatedWork W2794773176 @default.
• W2507795054 hasRelatedWork W2798115114 @default.
• W2507795054 hasRelatedWork W2983482650 @default.
• W2507795054 hasRelatedWork W3184357652 @default.
• W2507795054 hasRelatedWork W4241970211 @default.
• W2507795054 hasRelatedWork W4254421610 @default.
• W2507795054 hasVolume "122" @default.
• W2507795054 isParatext "false" @default.
• W2507795054 isRetracted "false" @default.
• W2507795054 magId "2507795054" @default.
• W2507795054 workType "article" @default.